April 08, 2026

AAD Issues Pediatric Atopic Dermatitis Guidelines

Two companion guidelines provide 41 evidence-based recommendations on treatment and prevention, along with 29 statements on comorbidity associations in patients under 18

Conexiant

April 01, 2026

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

Conexiant

March 30, 2026

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Explore the latest advances in metastatic melanoma treatment from leading experts at Mass General Hospital.

JADPRO

March 24, 2026

Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could...

The ASCO Post

March 24, 2026

Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrenc...

The ASCO Post

February 24, 2026

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

In an interim analysis of a phase III trial (KEYVIBE-010) reported in The Lancet Oncology, Dummer et al found that adjuvant therapy with a coformulation of the anti-TIGIT antibody vibostolimab with pe...

The ASCO Post

February 19, 2026

Stage II Melanoma: Adjuvant Pembrolizumab and Risk of New Skin Cancers

Is prior adjuvant pembrolizumab associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma? A secondary analysis of the phase III KEYN...

The ASCO Post

February 09, 2026

Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy

The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting.

The ASCO Post

February 06, 2026

World Cancer Day: Taking a Proactive Approach to the Most Commonly Diagnosed Cancer

On World Cancer Day, marked annually on February 4, it’s important to note that skin cancer is the most frequently diagnosed cancer. One in every five Americans will experience some form of skin cancer by age 70, experts say.

Baptist Health South Florida

February 06, 2026

Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans

Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published...

The ASCO Post